<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - FLECAINIDE ACETATE</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>FLECAINIDE ACETATE</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#hepaticImpairment" data-toggle="tab">Hepatic impairment</a></li>
          <li><a href="#renalImpairment" data-toggle="tab">Renal impairment</a></li>
          <li><a href="#contraindications" data-toggle="tab">Contra indications</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#directionsForAdministration" data-toggle="tab">Administration</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#monitoringRequirements" data-toggle="tab">Monitoring requirements</a></li>
          <li><a href="#unlicensedUse" data-toggle="tab">Unlicensed use</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">AV nodal reciprocating tachycardia, arrhythmias associated with accessory conducting pathways (e.g. Wolff-Parkinson-White syndrome), disabling symptoms of paroxysmal atrial fibrillation in patients without left ventricular dysfunction (arrhythmias of recent onset will respond more readily) (specialist supervision in hospital)</span>,
                <span class="indication">Ventricular tachyarrhythmias resistant to other treatment (specialist supervision in hospital)</span>,
            </h4>
            <p class="specificity"><span class="route">Initially by slow intravenous injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 2 mg/kg (max. per dose 150 mg), to be given over 10&#8211;30 minutes with ECG monitoring, followed by (by intravenous infusion) 1.5 mg/kg/hour if required for 1 hour, then (by intravenous infusion) reduced to 100&#8211;250 micrograms/kg/hour for up to 24 hours, maximum cumulative dose of 600 mg in first 24 hours, then transfer to oral treatment.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Supraventricular arrhythmias</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth using modified-release medicines</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 50 mg twice daily, (by mouth) increased if necessary up to 300 mg daily.</li>
              <li class="dose adult"><strong>For adults </strong><br/>
                200 mg daily.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Ventricular arrhythmias (initiated under direction of hospital consultant)</span>,
            </h4>
            <p class="specificity"><span class="route">Initially by mouth using immediate-release medicines</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 100 mg twice daily for 3&#8211;5 days, maximum 400 mg daily reserved for rapid control or in heavily built patients, then (by mouth) maintenance, reduce to the lowest dose that controls the arrhythmia.</li>
            </ul>
          </section>
        </section>
        
        
            <section class="doseEquivalence">
                <h3>Dose equivalence and conversion</h3>
              <p>Patients stabilised on 200&#8239;mg daily immediate release flecainide may be transferred to modified-release medicines.</p>
            </section>
        
        
        
      </section>



      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <p>Used in pregnancy to treat maternal and fetal arrhythmias in specialist centres; toxicity reported in <i>animal</i> studies; infant hyperbilirubinaemia also reported.</p>
            </section>
      </section>

      <section class="tab-pane" id="hepaticImpairment">
        <h2>Advice regarding hepatic impairment</h2>

            <section class="doseAdjustments">
              <p>Avoid or reduce dose in severe impairment.</p>
            </section>
      </section>

      <section class="tab-pane" id="renalImpairment">
        <h2>Advice regarding renal impairment</h2>

            <section class="doseAdjustments">
              <p>Reduce initial oral dose to max. 100&#8239;mg daily or reduce intravenous dose by 50%, if eGFR less than 35&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p>
            </section>
        
      </section>

      <section class="tab-pane" id="contraindications">
        <h2>Contra indications</h2>

          <ul>
            <li>Abnormal left ventricular function</li>
            <li>atrial conduction defects (unless pacing rescue available)</li>
            <li>bundle branch block (unless pacing rescue available)</li>
            <li>control of arrhythmias in acute situations (for modified-release forms only)</li>
            <li>distal block (unless pacing rescue available)</li>
            <li>haemodynamically significant valvular heart disease</li>
            <li>heart failure</li>
            <li>history of myocardial infarction and either asymptomatic ventricular ectopics or asymptomatic non-sustained ventricular tachycardia</li>
            <li>long-standing atrial fibrillation where conversion to sinus rhythm not attempted</li>
            <li>second-degree or greater AV block (unless pacing rescue available)</li>
            <li>sinus node dysfunction (unless pacing rescue available)</li>
          </ul>
      </section>

      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> Asthenia, dizziness, dyspnoea, fatigue, fever, oedema, pro-arrhythmic effects, visual disturbances,
              </p>
              <p>
                <strong>rare:</strong> Amnesia, confusion, convulsions, depression, dyskinesia, hallucinations, peripheral neuropathy, pneumonitis,
              </p>
              <p>
                <strong>notKnown:</strong> Anaemia, anorexia, anxiety, ataxia, corneal deposits, drowsiness, flushing, gastrointestinal disturbances, headache, hepatic dysfunction, hypersensitivity reactions, increased antinuclear antibodies, increased sweating, insomnia, leucopenia, paraesthesia, photosensitivity, rash, syncope, thrombocytopenia, tinnitus, tremor, urticaria, vertigo,
              </p>
        
        
        
      </section>

      <section class="tab-pane" id="directionsForAdministration">
        <h2>Directions for administration</h2>

            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use</h3>
              <p>For <i>intravenous infusion</i> (<i>Tambocor</i>
            <tm tmtype="reg"/>), give continuously or intermittently in Glucose 5% or Sodium Chloride 0.9%. Minimum volume in infusion fluids containing chlorides 500&#8239;mL.</p>
            </section>
      </section>




      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            Atrial fibrillation following heart surgery
          </li>
          <li>
            elderly (accumulation may occur)
          </li>
          <li>
            patients with pacemakers (especially those who may be pacemaker dependent because stimulation threshold may rise appreciably)
          </li>
        </ul>
      </section>


      <section class="tab-pane" id="monitoringRequirements">
        <h2>Monitoring requirements</h2>

        
          <h3>Patient parameters</h3>
        
            <section class="patientParameters">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use</h3>
              <p>ECG monitoring and resuscitation facilities must be available.</p>
            </section>
      </section>

      <section class="tab-pane" id="unlicensedUse">
        <h2>Unlicensed use</h2>

            <section class="unlicensedUse">
              <p>Capules, tablets and injections: AV nodal reciprocating tachycardia, arrhythmias associated with accessory conducting pathways (e.g. Wolff-Parkinson-White syndrome), disabling symptoms of paroxysmal atrial fibrillation in patients without left ventricular dysfunction (arrhythmias of recent onset will respond more readily. </p><p>Immediate-release tablets only: symptomatic sustained ventricular tachycardia, disabling symptoms of pre- mature ventricular contractions or non-sustained ventricular tachycardia in patients resistant to or intolerant of other therapy.</p><p>Injection only: ventricular tachyarrhythmias resistant to other treatment.</p>
            </section>
      </section>










      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of FLECAINIDE ACETATE</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        
          <strong>Forms available from special-order manufacturers include: </strong>
            oral suspension,
            oral solution,

            <div id="PHP74959"><a href="../medicinalForm/PHP74959.html" data-target="#PHP74959" data-action="load">Tablet</a></div>
            <div id="PHP74970"><a href="../medicinalForm/PHP74970.html" data-target="#PHP74970" data-action="load">Modified-release capsule</a></div>
            <div id="PHP74965"><a href="../medicinalForm/PHP74965.html" data-target="#PHP74965" data-action="load">Solution for injection</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
